Description

Simple

Clinical

Overview

Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery. It is known to bind and block the activity of plasma cholinesterases.

Pharmacology

Indication

Used as an adjunct with succinylcholine (or suxamethonium chloride) to prolong muscle relaxation and to prevent succinylcholine-induced muscle fasciculations.

Pharmacodynamic

Hexafluronium bromide is a cholinesterase antagonist that can be used to prolong the relaxation effects of succinylcholine or suxamethonium chloride. Suxamethonium acts as a depolarizing muscle relaxant. It imitates the action of acetylcholine at the neuromuscular junction and is degraded by pseudoc... Read more

Mechanism of action

Hexafluronium bromide is a non-competitive reversible inhibitor of human plasma cholinesterase or pseudocholinesterase.
Hexafluornium probably binds to anionic side receptors near the active center, causing a conformational change in the enzyme, preventing acylation of the esteratic site. The ester... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

LD50 = 280 mg/kg (mouse, oral)

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Hexafluronium
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
The therapeutic efficacy of Hexafluronium can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Hexafluronium is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acebutolol
Hexafluronium may increase the bradycardic activities of Acebutolol.
Acepromazine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Aceprometazine.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Hexafluronium.
Acetophenazine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Acetophenazine.
Acetylcholine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Acetylcholine.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Acetylglycinamide chloral hydrate.
Aclidinium
The therapeutic efficacy of Aclidinium can be decreased when used in combination with Hexafluronium.
Acotiamide
The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Acotiamide.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Hexafluronium.
Adipiplon
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Adipiplon.
Agmatine
The therapeutic efficacy of Agmatine can be decreased when used in combination with Hexafluronium.
Agomelatine
The risk or severity of adverse effects can be increased when Hexafluronium is combined with Agomelatine.